Major Bleeding in Rivaroxaban Users with Non-Valvular Atrial Fibrillation in an Older Adult Population

被引：0
|
作者：
Tamayo, S. [1 ]
Patel, M. [2 ]
Yuan, Z. [3 ]
Sicignano, N. [4 ]
Hopf, K. [4 ]
Peacock, F. [5 ]
机构：
[1] Naval Med Ctr Portsmouth, Portsmouth, VA USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Janssen Res & Dev LLC, Titusville, NJ USA
[4] Hlth ResearchTx LLC, Trevose, PA USA
[5] Baylor Coll Med, Houston, TX 77030 USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2015年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
C175
引用
收藏
页码：S221 / S221
页数：1
相关论文
共 50 条
  • [1] POST-MARKETING PHARMACOVIGILANCE STUDY FOR THE ACTIVE DETECTION AND EVALUATION OF MAJOR BLEEDING IN RIVAROXABAN USERS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Tamayo, Sally
    Patel, Manesh
    Yuan, Zhong
    Hopf, Kathleen
    Peacock, W. Frank
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A281 - A281
  • [2] Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population
    Amin, A.
    Keshishian, A.
    Trocio, J.
    Dina, O.
    Le, H.
    Rosenblatt, L.
    Mardekian, J.
    Zhang, Q.
    Baser, O.
    Liu, X.
    Vo, L.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 964 - 964
  • [3] Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
    Abdullah, Ahmad Salihin
    Tan, Hwee Pheng
    Mohd Saffian, Shamin
    [J]. MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2022, 29 (02): : 164 - 172
  • [4] Major bleeding in a post-marketing assessment of 39,052 non-valvular atrial fibrillation patients on rivaroxaban
    Peacock, W. F.
    Patel, M.
    Tamayo, S.
    Sicignano, N.
    Hopf, K.
    Yuan, Z.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 687 - 687
  • [5] Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
    Chan, Yi-Hsin
    Yeh, Yung-Hsin
    Tu, Hui-Tzu
    Kuo, Chi-Tai
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    See, Lai-Chu
    [J]. ONCOTARGET, 2017, 8 (58) : 98898 - 98917
  • [6] Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
    Xiao-qin Liu
    Yu-fei Zhang
    Hong-yan Ding
    Ming-ming Yan
    Zheng Jiao
    Ming-kang Zhong
    Chun-lai Ma
    [J]. Acta Pharmacologica Sinica, 2022, 43 : 2723 - 2734
  • [7] Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
    Liu, Xiao-qin
    Zhang, Yu-fei
    Ding, Hong-yan
    Yan, Ming-ming
    Jiao, Zheng
    Zhong, Ming-kang
    Ma, Chun-lai
    [J]. ACTA PHARMACOLOGICA SINICA, 2022, 43 (10) : 2723 - 2734
  • [8] Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation
    Tamayo, Sally G.
    Simeone, Jason C.
    Nordstrom, Beth L.
    Patel, Manesh R.
    Yuan, Zhong
    Sicignano, Nicholas M.
    Peacock, W. Frank
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (10) : 1144 - 1146
  • [9] Risk of Stroke and Major Bleeding for Dabigatran, Rivaroxaban, and Warfarin Compared to Apixaban Among Non-Valvular Atrial Fibrillation Patients in the United States Medicare Population
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Dina, Oluwaseyi
    Le, Hannah
    Rosenblatt, Lisa
    Liu, Xianchen
    Mardekian, Jack
    Zhang, Qisu
    Baser, Onur
    Vo, Lien
    [J]. CIRCULATION, 2017, 136
  • [10] Rivaroxaban in Non-Valvular Atrial Fibrillation: a Prospective Studies and Clinical Practice
    Fonyakin, A. V.
    [J]. KARDIOLOGIYA, 2016, 56 (08) : 87 - 92
12345